Were William Guyer’s Corcept (CORT) share sales under a 10b5-1 plan?

Yes. The Form 4 states that the transaction was made pursuant to a Rule 10b5-1 trading plan adopted on November 27, 2024. Such pre-arranged plans schedule trades in advance, helping separate routine portfolio management from discretionary timing decisions.

Corcept CDO exercises options, sells 20K shares

Corcept Therapeutics’ Chief Development Officer William Guyer exercised stock options and sold shares on May 5, 2026.

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

Rhea-AI Filing Summary

Corcept Therapeutics’ Chief Development Officer William Guyer exercised stock options and sold shares on May 5, 2026. He exercised options to acquire 20,000 shares of common stock at $21.65 per share, then sold 20,000 shares in an open-market transaction at a weighted average price of $51.83 per share, with actual prices ranging from $51.60 to $52.05. Following these transactions, he directly holds 2,231 common shares, which include 224 and 498 shares underlying unvested restricted stock awards that each vest in full one year after their respective grant dates if conditions are met. He also holds 170,000 fully exercisable stock options with a $21.65 exercise price expiring on September 1, 2031. The sale was executed under a pre-arranged Rule 10b5-1 trading plan adopted on November 27, 2024.

Insider Trade Summary 10b5-1

Exercise and Sale: 20,000 shares ($604K approx. pre-tax spread)

Exercise and Sale 3 txns

Insider Guyer William

Role Chief Development Officer

Sold 20,000 shs ($1.04M)

Approx. gross sale proceeds $1.04M

Approx. exercise cost $433K

Approx. pre-tax spread $604K

Type	Security	Shares	Price	Value
Exercise	Stock Option (right to buy)	20,000	$0.00	$0.00
Exercise	Common Stock	20,000	$21.65	$433K
Sale	Common Stock	20,000	$51.83	$1.04M

Holdings After Transaction: Stock Option (right to buy) — 170,000 contracts (Direct); Common Stock — 2,231 shares (Direct)

Footnotes (4)

F1. Includes 224 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 1, 2025 and 498 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 2, 2026. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements.
F2. This transaction was made pursuant to a 10b5-1 plan adopted by the Reporting Person on November 27, 2024 in effect at the time of this transaction.
F3. Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $51.60 to $52.05 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.
F4. Fully exercisable.

Key Figures

Shares sold: 20,000 shares Sale price (weighted average): $51.83 per share Options exercised: 20,000 shares +5 more

8 metrics

Shares sold 20,000 shares Open-market sale of common stock on May 5, 2026

Sale price (weighted average) $51.83 per share Weighted average price for 20,000 shares sold; range $51.60–$52.05

Options exercised 20,000 shares Common stock acquired via option exercise at $21.65

Option exercise price $21.65 per share Stock option (right to buy) exercise price

Shares held after transactions 2,231 shares Direct common stock holdings following sale and exercise

Remaining options 170,000 options Fully exercisable options at $21.65 expiring September 1, 2031

Unvested restricted shares 224 and 498 shares Restricted stock awards from December 1, 2025 and March 2, 2026

Sale price range $51.60–$52.05 per share Actual prices for shares sold within the reported transaction

Key Terms

Rule 10b5-1 plan, restricted stock awards, Stock Option (right to buy), weighted average sale price

4 terms

Rule 10b5-1 plan financial

"This transaction was made pursuant to a 10b5-1 plan adopted by the Reporting Person on November 27, 2024"

A Rule 10b5-1 plan is a prearranged, written schedule that lets corporate insiders buy or sell company stock at set times or amounts, even if they later learn material nonpublic information. Think of it like setting an automatic thermostat for trades: it creates a clear record that trades were planned in advance, reducing the risk of insider-trading accusations and helping investors trust that insider transactions are routine rather than based on secret information.

restricted stock awards financial

"Includes 224 shares underlying unvested restricted stock awards granted ... and 498 shares underlying unvested restricted stock awards"

Restricted stock awards are company shares given to employees or executives that cannot be sold or transferred until certain conditions — like staying with the company for a set time or meeting performance targets — are met, like a gift that is locked in a safe until rules are satisfied. Investors care because these awards tie management’s pay to company performance, can increase the number of shares outstanding when they become tradable (dilution), and may signal expected future selling pressure or commitment to long-term growth.

Stock Option (right to buy) financial

"Stock Option (right to buy) ... underlying security title Common Stock"

weighted average sale price financial

"Represents the weighted average sale price for the entire number of shares sold"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Corcept (CORT) executive William Guyer report in this Form 4?

William Guyer reported exercising 20,000 stock options at $21.65 and selling 20,000 shares of Corcept common stock at a weighted average price of $51.83 per share, as part of his equity compensation and trading activity.

How many Corcept (CORT) shares did William Guyer sell and at what price?

He sold 20,000 shares of Corcept common stock in an open-market transaction at a weighted average price of $51.83 per share, with individual sale prices ranging from $51.60 to $52.05 according to the Form 4 footnote disclosure.

What options did William Guyer exercise in Corcept (CORT) stock?

He exercised stock options covering 20,000 shares of Corcept common stock at an exercise price of $21.65 per share. After this exercise, 170,000 stock options with the same $21.65 exercise price remain outstanding and fully exercisable until September 1, 2031.

How many Corcept (CORT) shares does William Guyer hold after these transactions?

After the reported transactions, William Guyer directly holds 2,231 shares of Corcept common stock. This amount includes 224 and 498 shares underlying unvested restricted stock awards that are scheduled to vest in full one year after their respective grant dates.

What are the terms of William Guyer’s remaining Corcept (CORT) stock options?

He holds 170,000 fully exercisable stock options with an exercise price of $21.65 per share, expiring on September 1, 2031. These options give him the right to buy Corcept common shares at that fixed price before the expiration date.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Accepted by SEC EDGAR 05/07/2026 - 04:30 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Guyer William

(Last)

(First)

(Middle)

C/O CORCEPT THERAPEUTICS INCORPORATED

101 REDWOOD SHORES PARKWAY

(Street)

REDWOOD CITY

CALIFORNIA

94065

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
CORCEPT THERAPEUTICS INC [ CORT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	Chief Development Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/05/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	05/05/2026		M		20,000	A	$21.65	22,231⁽¹⁾	D
Common Stock	05/05/2026		S⁽²⁾		20,000	D	$51.83⁽³⁾	2,231⁽¹⁾	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Stock Option (right to buy)	$21.65	05/05/2026		M			20,000	⁽⁴⁾	09/01/2031	Common Stock	20,000	$0	170,000	D

Explanation of Responses:

1. Includes 224 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 1, 2025 and 498 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 2, 2026. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements.

2. This transaction was made pursuant to a 10b5-1 plan adopted by the Reporting Person on November 27, 2024 in effect at the time of this transaction.

3. Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $51.60 to $52.05 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.

4. Fully exercisable.

Remarks:

The power of attorney under which this form was signed is on file with the Commission.

	/s/ Joseph Douglas Lyon, as attorney-in-fact for William Guyer	05/07/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR